Hiroshi Shiku Selected Research

HER2p63 peptide

5/2002

Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Shiku Research Topics

Disease

104	Neoplasms (Cancer) 01/2024 - 04/2002
19	Testicular Neoplasms (Testicular Cancer) 12/2023 - 03/2006
14	Disseminated Intravascular Coagulation 04/2006 - 06/2002
13	Leukemia 01/2018 - 03/2002
10	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 03/2002
9	Melanoma (Melanoma, Malignant) 11/2021 - 02/2008
8	Sarcoma (Soft Tissue Sarcoma) 12/2023 - 03/2005
8	Lymphoma (Lymphomas) 08/2008 - 01/2003
6	Inflammation (Inflammations) 01/2016 - 08/2006
5	Neoplasm Metastasis (Metastasis) 12/2023 - 09/2002
5	Esophageal Squamous Cell Carcinoma 12/2023 - 04/2019
5	Esophageal Neoplasms (Esophageal Cancer) 11/2021 - 11/2008
5	Thrombosis (Thrombus) 04/2006 - 07/2003
5	Infections 04/2006 - 06/2002
4	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 01/2005
4	Lung Neoplasms (Lung Cancer) 06/2020 - 01/2005
4	Multiple Myeloma 02/2008 - 01/2004
3	Cytokine Release Syndrome 01/2023 - 01/2019
3	Prostatic Neoplasms (Prostate Cancer) 06/2020 - 09/2002
3	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2020 - 06/2013
3	Glioma (Gliomas) 06/2013 - 01/2012
3	Carcinoma (Carcinomatosis) 05/2010 - 04/2002
3	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2007 - 07/2005
3	Thrombotic Thrombocytopenic Purpura 01/2007 - 05/2002
3	Acute Promyelocytic Leukemia 04/2006 - 09/2003
2	Disease Progression 12/2023 - 01/2003
2	Synovial Sarcoma (Synovioma) 12/2023 - 04/2019
2	Graft vs Host Disease (Graft-Versus-Host Disease) 11/2023 - 10/2023
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2014
2	Colorectal Neoplasms (Colorectal Cancer) 10/2020 - 04/2002
2	Head and Neck Neoplasms (Head and Neck Cancer) 06/2020 - 03/2013
2	Stomach Neoplasms (Stomach Cancer) 06/2020 - 01/2019
2	Wilms Tumor (Wilm's Tumor) 01/2018 - 06/2013
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 08/2015 - 04/2004
2	Renal Cell Carcinoma (Grawitz Tumor) 03/2013 - 01/2007
2	Necrosis 04/2008 - 04/2006

Drug/Important Bio-Agent (IBA)

56	AntigensIBA 12/2023 - 09/2003
21	Proteins (Proteins, Gene)FDA Link 12/2023 - 04/2002
14	Messenger RNA (mRNA)IBA 06/2020 - 04/2003
14	Dacarbazine (DIC)FDA LinkGeneric 04/2006 - 06/2002
13	Peptides (Polypeptides)IBA 01/2023 - 05/2002
12	CytokinesIBA 10/2023 - 01/2005
12	EpitopesIBA 11/2022 - 09/2003
12	Cancer VaccinesIBA 01/2022 - 11/2003
11	VaccinesIBA 01/2023 - 12/2006
11	pullulanIBA 01/2023 - 05/2003
10	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023 - 08/2011
10	Neoplasm Antigens (Tumor Antigens)IBA 10/2015 - 10/2008
9	Chimeric Antigen ReceptorsIBA 01/2024 - 01/2013
8	Monoclonal AntibodiesIBA 04/2020 - 05/2003
7	Thromboplastin (Tissue Factor)IBA 01/2006 - 04/2002
5	GlucocorticoidsIBA 01/2024 - 07/2009
5	polyethylene glycol polyethyleneimine nanogelIBA 01/2023 - 09/2014
5	FibrinIBA 01/2006 - 01/2003
5	fibrin fragment D (D-dimer)IBA 01/2006 - 01/2003
4	HLA-A Antigens (HLA-A)IBA 01/2024 - 07/2006
4	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2024 - 07/2009
4	Biomarkers (Surrogate Marker)IBA 11/2022 - 06/2009
4	AntibodiesIBA 01/2019 - 09/2003
4	AutoantigensIBA 01/2016 - 09/2003
4	Hemostatics (Antihemorrhagics)IBA 01/2006 - 01/2003
4	Fibrinogen (Factor I)FDA Link 07/2005 - 01/2003
3	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2019
3	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 09/2003
3	Surface Antigens (Surface Antigen)IBA 01/2022 - 01/2016
3	Combined VaccinesIBA 11/2021 - 02/2004
3	EnzymesIBA 01/2019 - 01/2005
3	LigandsIBA 01/2017 - 09/2010
3	MethylcholanthreneIBA 08/2009 - 06/2005
3	CholesterolIBA 05/2007 - 01/2005
3	thiamine triphosphorate (TTP)IBA 01/2007 - 05/2002
3	Inosine Triphosphate (ITP)IBA 01/2007 - 07/2005
3	C-Reactive ProteinIBA 08/2006 - 07/2005
3	Fibrin Fibrinogen Degradation ProductsIBA 10/2005 - 01/2005
3	formycin diphosphate (FDP)IBA 07/2005 - 01/2003
3	Thrombin FDA Link 03/2005 - 07/2002
3	Thomsen-Friedenreich antigenIBA 01/2005 - 07/2004
2	Small Interfering RNA (siRNA)IBA 11/2023 - 06/2013
2	Carcinoembryonic AntigenIBA 01/2023 - 01/2016
2	Protein Subunit VaccinesIBA 01/2023 - 09/2010
2	MicroRNAs (MicroRNA)IBA 11/2022 - 01/2016
2	Immunoglobulin A (IgA)IBA 11/2022 - 04/2002
2	Polysaccharides (Glycans)IBA 01/2022 - 05/2008
2	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2022 - 01/2005
2	NanogelsIBA 01/2022 - 03/2008
2	Immunoglobulin E (IgE)IBA 03/2018 - 12/2016
2	Immunoglobulin G (IgG)IBA 12/2016 - 09/2003
2	Aurora Kinase AIBA 01/2016 - 01/2012
2	Interleukin-10 (Interleukin 10)IBA 01/2014 - 09/2011
2	PicibanilIBA 04/2013 - 11/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2010 - 04/2008
2	AllergensIBA 01/2010 - 11/2008
2	Myeloblastin (Proteinase 3)IBA 04/2008 - 08/2006

Therapy/Procedure

40	Therapeutics 01/2024 - 02/2002
32	Immunotherapy 10/2023 - 02/2004
10	Drug Therapy (Chemotherapy) 01/2019 - 03/2002
5	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2023 - 01/2012
3	Aftercare (After-Treatment) 01/2019 - 01/2003
2	Oncolytic Virotherapy 05/2014 - 01/2014
2	Biological Therapy 05/2014 - 06/2009